About eyal

This author has not yet filled in any details.
So far eyal has created 84 blog entries.

Director, Quality Assurance

February 9th, 2016|


POSITION:    Director, Quality Assurance


LOCATION:  Fremont, CA – conveniently located near Dumbarton Bridge (hwy 84)


Company Background


Quark Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company, a leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs. Two products, which were granted Orphan designation, QPI -1002 and QP -1007 are in global phase III […]

Sr. Manager / Manager, Regulatory Affairs

January 13th, 2016|

Position Summary

The Sr. Manager/ Manager of Regulatory Affairs is responsible for the implementation of regulatory strategies and direction for assigned Quark Project Teams under the leadership of the Vice President of Regulatory Affairs and Quality Assurance.   S/he must have a comprehensive understanding of FDA/EU/ICH requirements, principles, concepts, industry practices, and standards.  In this hands-on role, […]

Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury

December 9th, 2015|

U.S. Patent No. 9,205,100, issued on December 8, 2015, relates to a novel method for treatment of lung disease or lung injury which is associated with lung transplantation. The patented method uses a proprietary combination of nucleic-acid inhibitors targeting two types of toll-like receptors, namely TLR2 and TLR4. Quark demonstrated that this novel inhibitor combination […]

Quark Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION

October 27th, 2015|

Fremont, Ca – October 27, 2015– Quark Pharmaceuticals, Inc, a late clinical-stage pharmaceutical company, who is a leader in the discovery and development of novel RNA interference (RNAi)-based therapeutics, announced today that it has initiated the U.S. arm of a global Phase II/III pivotal study (NCT02341560) of QPI-1007 for treatment of acute non arteritic anterior […]

Quark announces patent approval for Methods for treating eye disorders

September 1st, 2015|

The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at least one siRNA which down regulates expression of a target gene associated with loss […]

Quark will present at Eurotides 2015, Maritim proArte Hotel, Berlin, Germany ,16-18 Nov 2015

August 23rd, 2015|


Quark announces patent approval for Compositions and methods for treatment of ear disorders

July 28th, 2015|

The present invention relates to pharmaceutical compositions useful for topical, non-invasive delivery of an oligonucleotide to the ear and to methods for the treatment of an ear disorder, including hearing loss arising from chemical-induced ototoxicity, acoustic trauma and presbycusis; and microbial infections. The method comprises topically administering to the ear of a subject in need […]

Quark announces patent approval for therapeutic uses of inhibitors of RTP801

June 16th, 2015|

The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801 gene and/or protein.

Read More…

Quark announces patent approval for double stranded RNA compounds to RhoA and use thereof

June 2nd, 2015|

The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences […]

Quark announces patent approval for oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases

April 14th, 2015|

The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient […]